THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT. Esteban Burrone Head of Policy
|
|
- Wilfrid Nichols
- 5 years ago
- Views:
Transcription
1 THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT Esteban Burrone Head of Policy
2 LEARNING FROM THE HIV RESPONSE
3
4 EVOLUTION OF AIDS DRUG PRICES: Source: MSF (2008) Untangling the Web of Antiretroviral Price Reductions. Geneva: MSF.
5 FUNDING TO PROCURE TREATMENT Today: Approximately 16 million people on treatment in low and middle-income countries (UNAIDS data) At approximately USD 90 per patient per year for 1 st line treatment (WHO GPRM) Spending on ARVs approximately USD 1.5 billion Without low cost medicines (hypothetical): At USD 10,000 per patient per year Having 16 million people on treatment would have costed: USD 160 billion Or. If we only had USD 1.5 billion, we would be able to procure ARVs for 150,000 people
6 WHAT HAPPENED? First wave of ARVs became available from multiple (primarily Indian) generic manufacturers at affordable prices Strong activism and community mobilization Development of comprehensive treatment programs Significant donor funding and gradual stepping up in domestic resources Etc, etc, etc
7 WHAT HAPPENED? First wave of ARVs became available from multiple (primarily Indian) generic manufacturers at affordable prices Strong activism and community mobilization Development of comprehensive treatment programs Significant donor funding and gradual stepping up in domestic resources Etc, etc, etc
8 PATENTS ON NEW HIV MEDICINES COULD HAVE DELAYED ACCESS TO THE NEW MEDICINES MEDICINE PATENT EXPIRY (key patents only) Abacavir 2018 Atazanavir 2018/2019 Dolutegravir 2026 Elvitegravir/cobicistat 2024/2028 Lopinavir/ritonavir 2016/2024/2026 Raltegravir 2022/2025 Rilpivirine 2022 Tenofovir Disoproxil Fumarate 2017/18 Tenofovir Alafenamide 2021
9 ACCESS ORIENTED LICENSING Access oriented licensing became the norm in HIV, and increasingly one of the main mechanisms for access to affordable HIV medicines in many LMICs Can be bilateral or through the Medicines Patent Pool (MPP) and they allow generic manufacturers to make generic versions of patented medicines and supply LMICs Until 2015, this model had only existed in HIV.
10 WHAT IS THE MEDICINES PATENT POOL? Public health organization created in 2010 to increase access to quality, affordable medicines for people with HIV in LMICs Works by addressing a key challenge in HIV medicines access: sharing patents Established and fully funded by Facilitates competition to reduce prices and enables innovation in the form of new FDCs and paediatric medicines
11 THE MPP MODEL THE MEDICINES PATENT POOL (MPP) First patent pool in public health PATENT HOLDERS GENERIC MANUFACTURERS SubLicences Licences PEOPLE LIVING WITH HIV, HEPATITIS C OR TUBERCULOSIS Medicines ROYALTIES Initially working only in HIV. Expanded to HCV and TB in November Works through access oriented licences.
12 KEY FEATURES OF MPP LICENCES Broad geographical scope including 55 to 80% of MICs Transparent all licences are public Non-exclusive and non-restrictive to encourage competition Includes waivers on data exclusivity Strict quality assurance Compatible with use of TRIPS flexibilities Enable sales outside territory if no patents
13 MPP LICENCES GEOGRAPHICAL COVERAGE Product(s) Licensed LIC LMIC UMIC HIC Undefined Total Abacavir (paed.) Atazanavir Cobicistat Daclatasvir Dolutegravir (paed.) Dolutegravir Elvitegravir Lopinavir/Ritonavir (paed.) Lopinavir/Ritonavir (Africa) Raltegravir (paed.) Ravidasvir * Sutezolid (global) All TDF TAF
14 BENEFITING ALL STAKEHOLDERS Patent holders Effective way to make available innovative products in resource poor settings; licence management to ease transaction costs Low-cost producers Simplified approach to the development of affordable versions of existing medicines, create needed new formulations Treatment providers and donors An ability to stretch budgets to treat more people with WHO-recommended medicines People living with HIV Gain faster access to quality, appropriate, affordable and life-saving treatments
15 APPLYING THE MODEL TO THE VIRAL HEPATITIS RESPONSE
16 PATENTS ON HBV AND HCV MEDICINES MEDICINE BRAND NAME PATENT EXPIRY MAIN PATENT (SECONDARY PATENTS) Tenofovir disoproxil fumarate (TDF) Viread 2017 (2018) Tenofovir alafenamide (TAF) Vemlidy 2021 Daclatasvir Daklinza 2027 (2030) Sofosbuvir Sovaldi 2024 (2028/2032) Sofosbuvir/ledipasvir Harvoni 2030 (2033) Sofosbuvir/velpatasvir Eplclusa 2031 (2034) Glecaprevir/pibrentasvir Maviret 2031 (2035) Sofosbuvir/velpatasvir/voxilaprevir Vosevi 2033 (2034) Source:
17 LICENCES FOR MARKETED VIRAL HEPATITIS B AND C MEDICINES Medicine(s) Tenofovir disoproxil fumarate (TDF) Tenofovir Alafenamide (TAF) Brand Name Viread Vemlidy Indication MPP Licence Hepatitis B (and HIV) Hepatitis B (and HIV) YES YES Countries 116 countries but few patents remaining are expiring in countries Daclatasvir Daklinza Hepatitis C YES 112 countries + Sofosbuvir Sovaldi Hepatitis C NO 105 countries Sofosbuvir/ledipasvir Harvoni Hepatitis C NO 105 countries Sofosbuvir/velpatasvir Eplclusa Hepatitis C NO 105 countries Source:
18 HOW TO FIND OUT WHICH COUNTRIES ARE IN LICENCES OR HAVE PATENTS ON A HEPATITIS MEDICINE? Most comprehensive source of information on the patent and licensing status of medicines for HIV, TB and Hepatitis in low and middle income countries Patent status data from over 110 low and middle income countries Covering 8 hepatitis C and 2 hepatitis B products Data exclusivity information from 15 countries Information on all relevant licences in LMICs
19 SEARCH EXAMPLE
20 MPP LICENCES IN HEPATITIS C: DACLATASVIR Product: Daclatasvir and combinations containing DCV (e.g. SOF/DCV) Geographical Scope: 112 countries (including ~ 75 MICs) Quality assurance: requirement to obtain approval from WHO PQ or stringent regulatory authority Royalties: royalty-free licence Transparency: licence public on MPP website
21 10 MPP sub-licensees working on the development, registration, manufacturing and/or distribution of DCV SUB-LICENSEES
22 TIMELINE FOR DACLATASVIR (DCV) Two years after MPP licence with BMS, multiple generics will be filing DCV and SOF/DCV for approval by WHO Prequalification (PQ) June 2014: DCV approved in Europe April 2015: DCV included in WHO EML April 2016: WHO guidelines recommend DCV Q4 2015: MPP signs licence with BMS Q4 2016: MPP licensees file DCV active ingredient with WHO Prequalification Q Q First MPP licensees filing DCV and SOF/DCV with WHO Prequalification
23 USD Per bottle PRICE DROPS IN INDIA Sofosbuvir Sofosbuvir/ledipasvir Daclatasvir Velpatasvir $450 $400 $384 $350 $330 $300 $285 $250 $205 $192 $200 $161 $169 $162 $143 $150 $108 $108 $97 $83 $93 $93 $100 $60 $92 $50 $55 $61 $61 $38 $30 $23 $0 Courtesy of Giten Khwairakpam (Treat Asia) Source: in collaboration with community networks in India
24 IS THE PROBLEM OF ACCESS TO AFFORDABLE, QUALITY-ASSURED MEDICINES SOLVED? NO! Local market authorization: low prices apply where there is competition. Many countries have no (or only one) locally registered product Quality assurance: Still only few companies have obtained WHO PQ for SOF, and none for other DAAs (DCV filings starting) Out of pocket payments: Without treatment programs, access price may still be too high for many Generic competition available in countries included in the licences or where products not patented (see MedsPaL.org) New drugs: new medicines like G/P could shorten treatment, facilitate treatment for specific populations
25 GLOBAL DONOR FUNDING FOR VIRAL HEPATITIS Some funding for HIV/HCV co-infection by Global Fund (e.g. Ukraine) UNITAID: project based funding EndHep 2030 Fund launched at World Hepatitis Summit 2017: Grant-making body to raise $ 1 billion Focus on capacity building and advocacy for sound public health policy development within the context of national health systems Managed by Rockefeller Philanthropy Advisors
26 HEPATITIS B TREATMENTS: TDF AND TAF Since at least 2011 most LMICs have had access to generic TDF In 2018 any remaining patents are expiring and generic TDF should be available globally Current generic price: USD 32 per year through international procurement (WHO GPRM) Price at which TDF is available in private markets in Sub-Saharan Africa: approx. USD 10 to USD 25 per month (source: patient groups) Procurement mechanisms for obtaining USD 32 price exist and can be used for TDF Generic TAF will be available from generics in 116 countries, with possibility of further price reductions (25mg vs. 300mg)
27 CONCLUSIONS - Access to affordable quality-assured medicines is key for elimination targets to be attainable - Medicines prices have come down considerably in many countries over past two years significantly reducing funding needs - Access-oriented licensing of hepatitis medicines have contributed significantly to price drops (as in HIV) - Challenges remain for actual access to quality-assured affordable medicines in-country - Access to affordable medicines can help trigger the response, but HBV example shows clearly not sufficient
28 Supported by:
INTRODUCTION TO THE MEDICINES PATENT POOL
www.medspal.org TABLE OF CONTENTS 1. Introduction to the Medicines Patent Pool 2. Background on MedsPaL 3. What patent information is included in MedsPaL? 4. What licensing and data exclusivity information
More informationUpdate on progress of MPP sublicensees
Update on progress of MPP sublicensees Medicines Patent Pool SEPTEMBER 2018 SUMMARY This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies) To date, MPP has signed
More informationUpdate on the Medicines Patent Pool
Update on the Medicines Patent Pool Sandeep Juneja November 06, 2012 How the Pool works* The Pool is an innovative licensing mechanism for HIV medicines Licensors Patents Feedback Market Impact Product
More informationUpdate on Progress of MPP Sub-licensees July 2017
HOW THE MPP WORKS? Update on Progress of MPP Sub-licensees July 2017 In-Licensing: Concluded Agreements Lopinavir Ritonavir (separate paediatrics and adults licences) Atazanavir Daclatasvir (HCV) Nevirapine
More informationHepatitis C. Graciela Diap X Congress of the SEMTSI Bilbao, 23 October 2017
Hepatitis C Graciela Diap X Congress of the SEMTSI Bilbao, 23 October 2017 Source: Polaris Observatory An estimated 70 million individuals are infected with HCV (viremic), a prevalence of ~1% in 2016 Prevalence
More informationThe Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland
The Medicines Patent Pool: An Update June 2012 Geneva, Switzerland The Medicines Patent Pool Royalties Licensor Licensor Patents Generics versions of existing compounds Licensor Licensor Patents Patents
More informationForecasting pipeline ARVs. Joseph Perriëns Sandeep Juneja Aastha Gupta
Forecasting pipeline ARVs Joseph Perriëns Sandeep Juneja Aastha Gupta Presently: lack of visibility causes a gap between demand and generic production for new drugs Patent Holder R&D Marketing 3-4 yrs
More informationSection 9: Tackling the Hepatitis C epidemic: a global landscape
Section 9: Tackling the Hepatitis C epidemic: a global landscape Céline Grillon (Médecins du Monde) Training Hepatitis C and HR for PWUD, 19 th -24 th Sept. 2016, Nairobi, Kenya Learning objective of the
More informationPatent Pools As Public Health Meta Collaborations: the Experience of NIH and the Medicines Patent Pool
Patent Pools As Public Health Meta Collaborations: the Experience of NIH and the Medicines Patent Pool Steven M. Ferguson, CLP Email: sf8h@nih.gov Deputy Director, Licensing & Entrepreneurship NIH Office
More informationChronic hepatitis C Building access into drug development: DNDi strategy
Chronic hepatitis C Building access into drug development: DNDi strategy July 2017 IAS Isabelle Andrieux-Meyer Head of HIV/HCV Clinical Programs Declaration of interests Isabelle Andrieux-Meyer from Drugs
More informationHepatitis and HIV Co-Infection: Situation in Ukraine.
2nd Central and Eastern European Meeting on Viral Hepatitis and Co-Infection with HIV Hepatitis and HIV Co-Infection: Situation in Ukraine. Pavlo Skala Associate Director: Policy & Partnership Ukraine
More informationTreatment and Access to Drugs
Treatment and Access to Drugs Presenter: Co-leads: Peter Beyer & Philippa Easterbrook WHO Regional Advisor for South East Asia (SEARO): Razia Narayan Pendse Session Objectives By the end of this session,
More informationThe Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations
Slide 1 The Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations Sébastien Morin (International AIDS Society, Switzerland) 9 th
More informationWHO Strategy and Goals for Viral Hepatitis Elimination
WHO Strategy and Goals for Viral Hepatitis Elimination No Disclosures Outline 1. Global strategy for elimination WHO targets and rationale 2. The global response so far Gaps in achieving the HBV and HCV
More informationWHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment Boniface Dongmo Nguimfack HIV/Technology and Commodities 1 AMDS
More informationPatents and licences on antiretrovirals: A snapshot
2014 Patents and licences on antiretrovirals: A snapshot APRIL 2014 UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211 Geneva 27 Switzerland T +41 22 791 55 03 F +41 22 791 48 90 unitaid@who.int
More informationGeneric HCV DAAs. Economics and sustainability. Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK
Generic HCV DAAs Economics and sustainability Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK Sunday, 23rd July 2017 Paris, France www.iasociety.org HCV DAAs can be made very
More informationInnovation, Access and Use Department of Essential Medicines and Health Products WHO
MARKETS FOR QUALITY-ASSURED PRODUCTS Sarah Garner and Francisco Blanco Innovation, Access and Use Department of Essential Medicines and Health Products WHO 1 Objectives Indicate market needs for medicines
More informationJohn Amis/AP Images for AIDS. Healthcare Foundation
John Amis/AP Images for AIDS Healthcare Foundation Sofosbuvir Bought in 2011 by Gilead for 11 billion: "a huge and risky bet on the next generation of hepatitis C treatments" (Reuters) Patent situation:
More informationAccess to hepatitis medicines
World Hepatitis Summit November 2 nd 2017 Access to hepatitis medicines Dr Andrew Hill, PhD, Department of Translational Medicine University of Liverpool, UK 1 Changes in HCV prevalence: 2016-2017 Worldwide,
More informationUNITAID is hosted and administered by the World Health Organization
UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211 Geneva 27 Switzerland T +41 22 791 55 03 F +41 22 791 48 90 unitaid@who.int www.unitaid.eu Medicines Patent Pool Chemin Louis-Dunant
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationREPORT FROM THE COMMISSION. Annual Report ( )
EUROPEAN COMMISSION Brussels, 18.12.2012 COM(2012) 775 final REPORT FROM THE COMMISSION Annual Report (-) on the application of Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion
More informationUniversal access to medicine: HIV and beyond
Universal access to medicine: HIV and beyond Dr Andrew Hill Department of Pharmacology and Therapeutics University of Liverpool United Kingdom UNAIDS STAC meeting, Lilongwe, May 15 th 2017 Universal access
More informationSection 6: Treatment of Hepatitis C virus (HCV)
Section 6: Treatment of Hepatitis C virus (HCV) Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective of the session: understanding
More informationEssential Medicines for Universal Health Coverage. Highlights of the report
Essential Medicines for Universal Health Coverage Highlights of the report Scope and process Prompted by the 30 th anniversary of the 1985 Nairobi Conference on the Rational Use of Drugs, to ask: 1. What
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationAccelerating Access to Simpler, Safer, and More Affordable HIV Treatment Through ART Optimization
Accelerating Access to Simpler, Safer, and More Affordable HIV Treatment Through ART Optimization What is antiretroviral treatment (ART) optimization? At its core, ART optimization is about ensuring that
More informationThe new WHO global injection safety policy and campaign
The new WHO global injection safety policy and campaign B. Allegranzi, SDS, HIS WHO/USAID/PEPFAR hosted webinar 20 August 2015 Overuse of injections and unsafe injection practices worldwide in 2000 (1)
More informationWHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES
WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES Immunization and vaccine development in the last decade Since the Millennium Summit in 2000, immunization substantial international
More informationAnnex 1 Cost Benefit Analysis for UNITAID Patent Pool 2
Annex 1 Cost Benefit Analysis for UNITAID Patent Pool 2 20 June 2008 Introduction The feasibility and sustainability of treatment for HIV/AIDS in developing countries will depend upon the ability of donors
More informationSimplified HCV Diagnostics
Simplified HCV Diagnostics Viral Hepatitis Elimination Meeting Amsterdam 2016 Dr Dmytro Donchuk HIV, TB and Viral Hepatitis Adviser For Dr Teri Roberts Diagnostic Adviser MSF SAMU and Access Campaign Speaker
More informationGuidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017
Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Scottish Health Protection Network HIV Clinical Leads FINAL Approved for circulation 17 May 2017 Version No. 6.2 (04/05/17) Date
More informationAccess to HCV treatment in Eastern Europe and Central Asia. Natalia Kravchenko (Alliance for Public Health) Liudmyla Maistat (Medicines Patent Pool)
Access to HCV treatment in Eastern Europe and Central Asia Natalia Kravchenko (Alliance for Public Health) Liudmyla Maistat (Medicines Patent Pool) Disclosure Presenter: Natalia Kravchenko FINANCIAL DISCLOSURE:
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationWHO WIPO WTO Trilateral symposium
WHO WIPO WTO Trilateral symposium Public Health, Intellectual Property, and TRIPS at 20: Innovation and Access to Medicines : Learning from the Past, Illuminating the Future Access to Medicines: Achievements
More informationPROGRESS REPORT ON ACCESS TO HEPATITIS C TREATMENT
PROGRESS REPORT ON ACCESS TO HEPATITIS C TREATMENT FOCUS ON OVERCOMING BARRIERS IN LOW- AND MIDDLE-INCOME COUNTRIES MARCH 2018 A patient holds her hepatitis C medicines at the MSF hepatitis C clinic at
More informationSUMMARY MEETING REPORT. Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service. Geneva, 7 8 May 2013
SUMMARY MEETING REPORT Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service Geneva, 7 8 May 2013 Department of HIV/AIDS HIV Technologies and Commodities May 2013 WHO/HIV/2013.6
More informationPRIORITIZATION OF HIV, HEPATITIS C AND TUBERCULOSIS MEDICINES FOR IN- LICENSING BY THE MEDICINES PATENT POOL
PRIORITIZATION OF HIV, HEPATITIS C AND TUBERCULOSIS MEDICINES FOR IN- LICENSING BY THE MEDICINES PATENT POOL - 2018 Prioritization of HIV, Hepatitis C and Tuberculosis Medicines for In-Licensing by the
More informationPatients First! Gilles Van Cutsem, MSF
Patients First! Patients First! Gilles Van Cutsem, MSF Access Campaign: 1999-2010 Bearing Witness We are not certain that by speaking we will necessarily be able to save lives, but we know for certain
More informationFinancing ART in low- and middleincome. Karl L. Dehne UNAIDS
Financing ART in low- and middleincome countries Karl L. Dehne UNAIDS Close the global resource gap by 2015 $6 billion annually, overall target (between $22 billion and $24 billion) Programmes must become
More informationScaling up screening, diagnostic and treatments for people living with HCV in 2014?
Scaling up screening, diagnostic and treatments for people living with HCV in 2014? Isabelle Andrieux-Meyer, MD Médecins Sans Frontières Access Campaign WHO Technical Briefing Seminar November 6 th,2014
More informationNEXT GENERATION DIRECT-ACTING ANTIVIRALS
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1: THE EXPEDITION-2 STUDY J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D.
More informationProjected Demand for HIV Diagnostic Tests
Projected Demand for HIV Diagnostic Tests John Stover, Yu Teng, Adebiyi Adesina, Eline Korenromp On behalf of the Diagnostics Forecasting Technical Working Group (CDC, CHAI, GFATM, PfSCM, UNAIDS, UNICEF,
More informationGPRM - Global Price Reporting Mechanism December Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2010
Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2010 A summary report from the Global Price Reporting Mechanism Contents Background and Methods................................
More informationDrug Class Review Monograph GPI Class 12 Antivirals
Drug Class Review Monograph GPI Class 12 Antivirals Review Time Frame: 02/2016 04/2017 Previous Class Review: 05/2016 Background: Antiviral agents are used to treat infections caused by viruses, including,
More informationThe role of market intelligence in access to anti-malarial medicines: funding, procurement, and policy
The role of market intelligence in access to anti-malarial medicines: funding, procurement, and policy Brenda Waning Boston University School of Medicine November 20, 2009 American Society of Tropical
More informationThe Crisis in. Vaccine Development
The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationQ&A on Second-Line HIV/AIDS Treatment
Q&A on Second-Line HIV/AIDS Treatment Q. What are second-line antiretrovirals? How are they different from first-line ARVs and why do they cost more? A. Over time, a patient s initial regimen of ARV medications
More informationUN Panel Discussion Millennium Development Goals. Ajay Singh Senior Director Dr Reddy s Laboratories 07 July 2010
UN Panel Discussion Millennium Development Goals Ajay Singh Senior Director Dr Reddy s Laboratories 07 July 2010 1 A role for everyone. North Large branded companies Strong engine of innovation Almost
More informationAccess update, registration & procurement strategies Barbara ROTH Pharmacist, TB supply - MSF
Treating Patient, Not Disease: People-Centered Approach 1-2 March, 2018, BISHKEK, KYRGYZSTAN Access update, registration & procurement strategies Barbara ROTH Pharmacist, TB supply - MSF EML Guidelines
More informationEssential Medicines: update on policies and standards
Essential Medicines: update on policies and standards Jane Robertson Technical Officer Health Technologies and Pharmaceuticals (HTP) WHO Regional Office for Europe Pharmaceutical sector is complex R&D
More informationDiagnostics product development projects
Page 0 Diagnostics product development projects Smiljka de Lussigny Technical Officer, HIV UNITAID Copenhagen, 23 September 2013 Page 1 1 2 3 About UNITAID HIV diagnostics market UNITAID s current investment
More informationCan we make first line ART better?
Can we make first line ART better? Dr Angela Hartwig 8 th SA AIDS Conference, Durban Skills Building Session 15 June 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationThe Global Fund & UNICEF Partnership
The Global Fund & UNICEF Partnership Prof Michel D. Kazatchkine Executive Director UNICEF Executive Board February 9 th, 2011 The Global Fund Millennium Development Goals 1. Eradicate extreme poverty and
More informationRolling up HCV treatment programs for PWIDs in Ukraine
Rolling up HCV treatment programs for PWIDs in Ukraine www.aph.or g.ua Ludmila Maistat Alliance for Public Health VHPB Meeting, Highlight undeserved groups for screening, prevention and treatment of viral
More informationSTRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL ( ) POLICY BRIEF
PROGRAMME NATIONAL DE LUTTE CONTRE LES HEPATITES STRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL (2019-2023) POLICY BRIEF 1 INVESTING IN THE FIGHT AGAINST HEPATITIS B AND C IN SENEGAL NATIONAL STRATEGIC
More informationAn innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria
UNITAID An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria ECOSOC Annual Ministerial Review (Regional Ministerial Meeting on Financing Strategies
More informationPolitics is medicine at a large scale
Politics is medicine at a large scale Medicine is a social science, and politics is nothing else but medicine on a large scale. Rudolph Virchow Our health is also fundamentally defined and determined by
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More information4th International HIV/Viral Hepatitis Co- Infection Meeting
INSTITUTIONAL STRAPLINE 4th International HIV/Viral Hepatitis Co- Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Approaches for simplified HCV diagnostics and screening algorithms: thoughts
More informationInvitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
More informationTreatment and Care: Product portfolio
Treatment and Care: Product portfolio Dr Paula Munderi MRC/UVRI Uganda Research Unit on AIDS EDCTP Stakeholder Meeting on HIV/AIDS 3-4 September 2013 Summary Brief overview HIV Treatment Pipeline Key Questions
More informationMÉDECINS SANS FRONTIÈRES ACCESS CAMPAIGN HIV & OPPORTUNISTIC INFECTION TREATMENT: SPOTLIGHT ON ACCESS GAPS
ISSUE BRIEF MÉDECINS SANS FRONTIÈRES ACCESS CAMPAIGN HIV & OPPORTUNISTIC INFECTION TREATMENT: SPOTLIGHT ON ACCESS GAPS This issue brief provides information regarding the changing product landscape, and
More informationFAST-TRACK COMMITMENTS TO END AIDS BY 2030
FAST-TRACK COMMITMENTS TO END AIDS BY 2030 FAST-TRACK COMMITMENTS TO END AIDS BY 2030 90-90-90 1 Ensure that 30 million people living with HIV have access to treatment through meeting the 90 90 90 targets
More informationOvercoming barriers to access to hepatitis C treatment in a rapidly changing landscape
Overcoming barriers to access to hepatitis C treatment in a rapidly changing landscape HIV/AIDS Department and Global Hepatitis Programme Dr. Stefan Wiktor Outline Global Hepatitis Strategy New HCV treatment
More informationProcurement, selection, prequalification, pricing and monitoring of medicines
Procurement, selection, prequalification, pricing and monitoring of medicines Richard Laing Medicines Information and Evidence for Policy, Essential Medicines and Pharmaceutical Policies World Health Organization
More informationThe Cost of Antiretrovirals
The Cost of Antiretrovirals Maximizing Value for Money Veronika J. Wirtz, National Institute of Public Health, Cuernavaca, Mexico Steven S. Forsythe, Futures Institute Atanacio Valencia Mendoza, National
More informationTHE ROADMAP. The HIV Drug Pipeline and its Patents. August
THE ROADMAP The HIV Drug Pipeline and its Patents August 2013 www.i-mak.org Table of Contents Abbreviations... Introduction & Methodology... Executive summary... Context... Summary guidance... Current
More informationPatient Forecasts for Pipeline ARVs: Adults
Patient Forecasts for Pipeline ARVs: Adults Presented at: WHO/UNAIDS Annual Meeting with ARV Manufacturers and Stakeholders March 19-20, 2015 Vineet Prabhu Market Intelligence Team, CHAI HIV Access Program
More informationGlobal vaccine market
Global vaccine market Global Vaccine and Immunization Research Forum Amie Batson Chief Strategy Officer, PATH March 2016 PATH/Eric Becker Agenda Overview of global vaccine market Demand Supply Financing
More informationAccess update, registration & procurement strategies Christophe PERRIN Pharmacist, TB supply - MSF
Tuberculosis in 2017: Searching for new solutions in the face of new challenges 6th TB Symposium Ministry of Health of the Republic of Belarus, Republican Scientific and Practical Center for Pulmonology
More informationViral Hepatitis Prevention Board CREATIVE FINANCING SOLUTIONS TO SCALE UP PREVENTION & TREATMENT OF HBV/HCV
Viral Hepatitis Prevention Board CREATIVE FINANCING SOLUTIONS TO SCALE UP PREVENTION & TREATMENT OF HBV/HCV vhpt-booklet-edits.indd 1 PUBLIC HEALTH TARGET WHO TARGETS TO CONTROL VIRAL HEPATITIS BY 2030
More informationImmediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts)
Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts) Roselyne TOBY,MD, ID specialist Infectious Disease Unit/Yaounde Central Hospital
More informationCADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs
CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs Meg Doherty, Treatment and Care Coordinator WHO HQ Outline What s new in ARV Guidelines Drug optimisation
More informationUNAIDS-World Bank Economics Reference Group for HIV & AIDS
UNAIDS-World Bank Economics Reference Group for HIV & AIDS HIV Programme Transition Nertila Tavanxhi, UNAIDS on behalf of the HIV Economics Reference Group HIV UNAIDS & WB HIV Economics Reference Group
More informationRifabutin for TB for people on ART
Rifabutin for TB for people on ART Reuben Granich WHO HIV/AIDS Department HIV/TB Core Group Meeting Addis Ababa, Ethiopia, 11-12 November 2008 Towards Universal Treatment Access Gains in Access to Care
More informationDiagnosis and monitoring of hepatitis C (HCV) in Morocco Current Status and strategies for universal access
Diagnosis and monitoring of hepatitis C (HCV) in Morocco Current Status and strategies for universal access Benchmarking HCV diagnostics, fibrosis evaluation, and treatment monitoring Pauline Londeix,
More informationOkinawa, Toyako, and Beyond: Progress on Health and Development
Okinawa, Toyako, and Beyond: Progress on Health and Development Prof. Michel D. Kazatchkine Executive Director The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations University, Tokyo,
More informationEffects of cobicistat on tenofovir exposure and its long-term tolerability: is it time to rethink at TAF trials?
Effects of cobicistat on tenofovir exposure and its long-term tolerability: is it time to rethink at TAF trials? Sara Baldelli 1, Andrea Giacomelli 2, Davide Minisci 2, Cristina Mazzali 3, Laura Milazzo
More informationLatest Funding Trends in AIDS Response
Latest Funding Trends in AIDS Response 20 th International AIDS Conference Melbourne, Australia J.V.R. Prasada Rao United Nations Secretary-General s Special Envoy for AIDS in Asia and the Pacific 21 July
More informationMODERN ART FOR AFRICA
MODERN ART FOR AFRICA March 2018 A guide for HIV treatment activists and communities in lowand middle-income countries ART today A pricing agreement was recently announced that will speed up access to
More informationHCV TREATMENT OPTIONS
HCV TREATMENT OPTIONS Trea2ng HCV is never an emergency, but early treatment prevents further liver damage. DAAs are easier to take, and be0er tolerated than PEG- IFN and RBV. Treatment is recommended
More informationUNITAID. Dr Philippe Duneton Deputy Executive Director Copenhagen September 2012
UNITAID Dr Philippe Duneton Deputy Executive Director Copenhagen September 2012 Challenges Achievements WHO Prequalification UNITAID support for prequalification of medicines Since 2007 UNITAID support
More informationCan we make first line ART better?
Can we make first line ART better? Dr David Stead Treatment Optimization HIV Clinicians Society Workshop 25 November 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS OVERVIEW OF PRESENTATION Introduction : lessons learnt Availability ; implications of making paediatric formulations available Remaining challenges in
More informationKey Messages for World Malaria Day 2009
INFORMATION RBM/WG/2009/INF.12 10 APR 2009 Draft document General distribution English Only Key Messages for World Malaria Day 2009 Counting Malaria Out to Reaching the 2010 Targets On the occasion of
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationMDR-TB: Medicine quality and rational use
MDR-TB: Medicine quality and rational use Hans V. Hogerzeil, MD, PhD, FRCP Edin Director, Essential Medicines and Pharmaceutical Policies WHO, Geneva 1 Can we rely on essential medicines against TB? (1)
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationAn Introduction to Access to Diagnostics. 14:00-14:45 BST 17 June
An Introduction to Access to Diagnostics 14:00-14:45 BST 17 June Chair: Dr Greg Martin, Specialist Registrar, Public Health Medicine and Editor-in- Chief of Globalization and Health @drgregmartin Speakers:
More informationTreatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationINTRODUCTION. WHO/Christopher Black
INTRODUCTION WHO/Christopher Black 7 1. BACKGROUND In 2016, an estimated 2.1 million children younger than 15 years and 17.8 million women were living with HIV worldwide (1). Despite advances in antenatal
More informationLaurus Labs Ltd (Laurus) -API leadership & R&D to drive growth
Laurus Labs Ltd (Laurus) -API leadership & R&D to drive growth 1 April 2018 Laurus Labs Ltd (Laurus) 31-03-2018 Recommendation : Buy CMP : Rs 503.00 Target : NA % Allocation : 5% Sector : Pharmaceuticals
More informationGlobal Prevalence of HBV, HCV, HIV
Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationUNITAID Increasing access to quality medicines and diagnostics for HIV/AIDS,TB and Malaria
UNITAID Increasing access to quality medicines and diagnostics for HIV/AIDS,TB and Malaria The HIV Medicines Patent Pool Initiative Briefing for Delegates to the 62 nd WHA, Geneva, 20 May 2009 Ellen 't
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More information